Divi's Laboratories Resultados de beneficios anteriores
Pasado controles de criterios 4/6
Los beneficios de Divi's Laboratories han disminuido a una tasa media anual de -0.2%, mientras que en la industria Life Sciences los beneficios crecieron en un 16.3% anualmente. Los ingresos han ido creciendo a una tasa media de 6.2% al año. La rentabilidad financiera de Divi's Laboratories es de 17.5%, y sus márgenes netos son de 26%.
Información clave
-0.19%
Tasa de crecimiento de los beneficios
-0.18%
Tasa de crecimiento del BPA
| Crecimiento de la industria Life Sciences | 11.24% |
| Tasa de crecimiento de los ingresos | 6.19% |
| Rentabilidad financiera | 17.45% |
| Margen neto | 26.05% |
| Última actualización de beneficios | 30 Jun 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • Aug 20
DIVISLAB: Upcoming June Quarter Results Will Support Bullish Outlook
Analysts have adjusted their price target on Divi's Laboratories from about ₹8,795 to about ₹10,953, reflecting updated views on its fair value, discount rate, revenue growth and profit margin assumptions, as well as the P/E they apply to the stock. What’s in the News for Divi's Laboratories Divi's Laboratories has scheduled a Board meeting on August 1, 2026.
Actualización de narrativa • Aug 06
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have nudged their fair value estimate for Divi's Laboratories higher from ₹5,610 to ₹6,000, citing a slightly lower discount rate, modestly adjusted revenue growth assumptions, and a small improvement in expected profit margins and future P/E levels. What's in the News for Divi's Laboratories Board meeting scheduled on May 23, 2026, to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Artículo de análisis • Aug 04
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
A week ago, Divi's Laboratories Limited ( NSE:DIVISLAB ) came out with a strong set of quarterly numbers that could...Actualización de narrativa • Jul 23
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have revised their price target for Divi's Laboratories to ₹5,610 from ₹5,333.98, citing updated assumptions for revenue growth, profit margins, and future P/E that collectively support a higher fair value estimate despite a slightly higher discount rate. What’s in the News for Divi's Laboratories A board meeting is scheduled on August 1, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Actualización de narrativa • Jul 08
DIVISLAB: Upcoming Board Decisions And Fair Value Assumptions Will Shape Balanced Outlook
Analysts have modestly raised their price target for Divi's Laboratories from ₹6,875 to approximately ₹7,059, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. What's in the News Divi's Laboratories has scheduled a board meeting on May 23, 2026, at 10:15 Indian Standard Time to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Actualización de narrativa • Jun 24
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have adjusted their fair value estimate for Divi's Laboratories slightly lower from ₹8,812.63 to ₹8,795.18, reflecting small tweaks to assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What’s in the News for Divi's Laboratories A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Actualización de narrativa • Jun 09
DIVISLAB: Upcoming Board Meeting And Dividend Decision Will Support Bullish Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹8,620.23 to ₹8,812.63, reflecting updated assumptions for the discount rate, revenue growth, profit margins and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 IST to review and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Actualización de narrativa • May 26
DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk
Analysts have lifted Divi's Laboratories price target from ₹5,133.17 to ₹5,333.98, citing updated assumptions on revenue growth, profit margins, and future P/E expectations. What's in the News A board meeting is scheduled for May 23, 2026, at 10:15 Indian Standard Time to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).Artículo de análisis • May 26
Divi's Laboratories Limited (NSE:DIVISLAB) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Divi's Laboratories Limited ( NSE:DIVISLAB ) last week reported its latest yearly results, which makes it a good time...Actualización de narrativa • May 04
DIVISLAB: Elevated Future P/E Will Remain A Key Overvaluation Risk
Analysts have trimmed their price target on Divi's Laboratories slightly from ₹5,140 to about ₹5,133, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E expectations. Valuation Changes Fair Value: Trimmed slightly from ₹5,140.00 to about ₹5,133.17 per share.Actualización de narrativa • Apr 20
DIVISLAB: Upcoming Board Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target for Divi's Laboratories slightly, with fair value now seen around ₹8,620 versus about ₹8,554 earlier, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled on Feb 11, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Actualización de narrativa • Apr 05
DIVISLAB: Elevated Future P/E Will Persist Despite Unchanged Fair Value Estimate
Analysts have maintained Divi's Laboratories' fair value estimate at ₹5,140 per share, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together guide the latest price target narrative. What's in the News Board meeting scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Actualización de narrativa • Mar 22
DIVISLAB: Upcoming Board Review And Fair Value Update Signal Constructive Outlook
Analysts have made a small upward adjustment to the fair value estimate for Divi's Laboratories to around ₹6,875, reflecting slightly updated assumptions on the discount rate, revenue growth, profit margins and future P/E. What's in the News Board meeting scheduled on February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Actualización de narrativa • Mar 08
DIVISLAB: Rich Future P/E Will Persist Despite Softer Outlook After Results
Analysts have trimmed their price target on Divi's Laboratories from ₹5,290 to ₹5,140, reflecting updated assumptions around a slightly lower revenue growth outlook, a marginally higher profit margin, a modestly reduced future P/E multiple, and an adjusted discount rate. What's in the News A board meeting is scheduled for February 11, 2026 to review and approve unaudited standalone and consolidated financial results for the quarter ended December 31, 2025 (Key Developments).Actualización de narrativa • Feb 22
DIVISLAB: Upcoming Results Review Will Shape Balanced Long Term Outlook
Narrative Update on Divi's Laboratories The analyst price target for Divi's Laboratories has been adjusted slightly higher from about ₹6,823 to roughly ₹6,870, with analysts pointing to small refinements in assumptions around discount rate, revenue growth, profit margin and future P/E as the drivers of this change. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Actualización de narrativa • Feb 07
DIVISLAB: Upcoming Results Review Will Support Bullish Long Term Outlook
Analysts have lifted their price target on Divi's Laboratories slightly to ₹6,823 from about ₹6,785, citing refreshed assumptions around discount rates, revenue growth, profit margin and future P/E that remain broadly in line with prior views. What's in the News A board meeting is scheduled for February 11, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Actualización de narrativa • Jan 24
DIVISLAB: Management Changes And Rich Future P/E Will Sustain Excessive Optimism
Analysts now cite slightly higher assumptions on growth, profitability and future P/E in their models for Divi's Laboratories, which feeds into an updated fair value estimate of ₹5,290, compared with the previous ₹5,035.89. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Actualización de narrativa • Jan 10
DIVISLAB: Upcoming Board Review And Management Changes Will Support Bullish Outlook
Analysts have raised their price target for Divi's Laboratories from ₹7,750 to about ₹8,554, citing updated assumptions related to revenue growth, profit margins and future P/E levels in their models. What's in the News Board meeting scheduled on Nov 07, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025 (company filing).Artículo de análisis • Dec 30
Earnings Not Telling The Story For Divi's Laboratories Limited (NSE:DIVISLAB)
Divi's Laboratories Limited's ( NSE:DIVISLAB ) price-to-earnings (or "P/E") ratio of 68.3x might make it look like a...Actualización de narrativa • Dec 25
DIVISLAB: Rising Profitability Expectations Will Mask Moderating Revenue And Justify Excessive Optimism
Analysts have raised their price target for Divi's Laboratories from ₹4,756 to ₹5,036, citing expectations of stronger profitability and a slightly richer future valuation multiple, despite moderating revenue growth assumptions. What's in the News Board meeting scheduled for November 7, 2025 at 10:30 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Actualización de narrativa • Dec 11
DIVISLAB: Upcoming Board Meeting And Leadership Review Will Shape Fair Outlook
Analysts have nudged their price target for Divi's Laboratories slightly higher, reflecting marginal improvements in discount rate assumptions and long term growth expectations that together support a fair value estimate of ₹6,785.10 per share. What's in the News Board meeting scheduled for November 7, 2025, at 10:30 IST to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).Artículo de análisis • Dec 09
Divi's Laboratories (NSE:DIVISLAB) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Actualización de narrativa • Nov 27
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have raised their fair value estimate for Divi's Laboratories from ₹6,433 to ₹6,785, citing modest improvements in revenue growth and profit margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, at 10:30 IST to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).Artículo de análisis • Nov 15
Investors Shouldn't Be Too Comfortable With Divi's Laboratories' (NSE:DIVISLAB) Earnings
Despite posting some strong earnings, the market for Divi's Laboratories Limited's ( NSE:DIVISLAB ) stock hasn't moved...Artículo de análisis • Nov 11
Divi's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Divi's Laboratories Limited ( NSE:DIVISLAB ) just released its latest interim results and things are looking bullish...Actualización de narrativa • Nov 08
DIVISLAB: Upcoming Board Decisions And Modest Earnings Improvements Will Shape Outlook
Analysts have modestly increased their price target for Divi's Laboratories from ₹6,363 to ₹6,433, citing slight improvements in projected revenue growth and profit margins as the underlying factors. What's in the News Upcoming Board Meeting scheduled for November 7, 2025, at 10:30 AM IST.Artículo de análisis • Sep 06
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
With a price-to-earnings (or "P/E") ratio of 69.2x Divi's Laboratories Limited ( NSE:DIVISLAB ) may be sending very...Actualización de narrativa • Sep 05
Custom Synthesis And Capacity Expansion Will Unlock Global Demand
With both the consensus price target and future P/E ratio for Divi's Laboratories remaining virtually unchanged, analysts signal stable valuation expectations, resulting in a steady fair value assessment at ₹6363. What's in the News Board meeting scheduled to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.
Nueva narrativa • Nov 10
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero Divi's Laboratories. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 26 | 112,300 | 29,250 | 15,280 | 0 |
| 31 Mar 26 | 105,600 | 25,680 | 14,600 | 0 |
| 31 Dec 25 | 103,140 | 24,790 | 14,260 | 0 |
| 30 Sep 25 | 100,290 | 24,850 | 13,560 | 0 |
| 30 Jun 25 | 96,520 | 23,060 | 13,060 | 0 |
| 31 Mar 25 | 93,600 | 21,910 | 12,580 | 0 |
| 31 Dec 24 | 90,780 | 20,670 | 12,020 | 0 |
| 30 Sep 24 | 86,140 | 18,360 | 11,730 | 0 |
| 30 Jun 24 | 81,850 | 16,740 | 11,350 | 0 |
| 31 Mar 24 | 78,450 | 16,000 | 11,060 | 0 |
| 31 Dec 23 | 74,926 | 13,834 | 10,670 | 0 |
| 30 Sep 23 | 73,456 | 13,314 | 10,380 | 0 |
| 30 Jun 23 | 72,906 | 14,774 | 10,040 | 0 |
| 31 Mar 23 | 77,670 | 18,240 | 9,870 | 0 |
| 31 Dec 22 | 83,353 | 23,971 | 9,851 | 0 |
| 30 Sep 22 | 91,208 | 29,925 | 9,908 | 0 |
| 30 Jun 22 | 92,538 | 31,054 | 9,827 | 0 |
| 31 Mar 22 | 89,599 | 29,605 | 9,571 | 0 |
| 31 Dec 21 | 82,297 | 25,678 | 9,154 | 0 |
| 30 Sep 21 | 74,379 | 21,362 | 9,044 | 0 |
| 30 Jun 21 | 71,996 | 20,493 | 8,736 | 0 |
| 31 Mar 21 | 69,695 | 19,843 | 8,367 | 0 |
| 31 Dec 20 | 65,710 | 18,705 | 7,950 | 0 |
| 30 Sep 20 | 62,658 | 17,590 | 7,179 | 0 |
| 30 Jun 20 | 59,620 | 15,962 | 6,641 | 0 |
| 31 Mar 20 | 53,945 | 13,765 | 6,317 | 0 |
| 31 Dec 19 | 52,719 | 12,803 | 5,995 | 0 |
| 30 Sep 19 | 52,356 | 13,106 | 5,824 | 0 |
| 30 Jun 19 | 51,139 | 13,575 | 5,694 | 0 |
| 31 Mar 19 | 49,463 | 13,527 | 5,525 | 0 |
| 31 Mar 18 | 38,915 | 8,770 | 4,651 | 0 |
| 31 Mar 17 | 40,643 | 10,604 | 5,090 | 0 |
| 31 Mar 16 | 37,764 | 11,258 | 3,669 | 277 |
Ingresos de calidad: DIVISLAB tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (26%) de DIVISLAB son superiores a los del año pasado (23.9%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de DIVISLAB han disminuido en un 0.2% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de DIVISLAB en el último año (26.8%) supera su media de 5 años (-0.2% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de DIVISLAB en el último año (26.8%) superó al de la industria Life Sciences 14.1%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de DIVISLAB (17.5%) se considera baja.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/23 22:37 |
| Precio de las acciones al final del día | 2026/08/21 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Divi's Laboratories Limited está cubierta por 53 analistas. 29 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Pranav Chawla | Ambit Capital |
| Gaurav Tinani | Ambit Capital |